相关实验视频
Updated: Jul 21, 2025

Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 25, 2016
口服奥雷克辛受体2在麻醉症类型1中的激动剂
Yves Dauvilliers1, Emmanuel Mignot1, Rafael Del Río Villegas1
1From the Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, and the University of Montpellier, INSERM Institute for Neurosciences of Montpellier - both in Montpellier, France (Y. Dauvilliers); the Stanford Department of Psychiatry and Behavioral Sciences, Center for Sleep Sciences and Medicine, Stanford University Medical School, Palo Alto, CA (E.M.); the Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, and Universidad CEU San Pablo, CEU Universities - both in Madrid (R.R.V.); Takeda Development Center Americas, Lexington (Y. Du, E.H., H.K., E.K., S.M., R.R., S.I.S., T.S., P.R., J.W., H.Z., N.V.M., C.H.), and the Department of Neurology, Division of Sleep Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (T.E.S.) - both in Massachusetts; Japan Somnology Center, Institute of Neuropsychiatry, and the Department of Somnology, Tokyo Medical University - both in Tokyo (Y.I.); the State Health Center, Budapest, Hungary (Z.S.); and IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, and the Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena - both in Italy (G.P.).
一种素受体2激素的TAK-994在1型麻醉症患者中改善了嗜睡和触觉性. 然而,由于一些参与者的严重肝损伤问题,该试验被提前停止.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 睡眠医学 睡眠医学
背景情况:
- 1型麻醉症的特征在于大脑中严重丧失奥雷克辛神经.
- 氨酸神经在调节清醒和睡眠方面发挥着至关重要的作用.
研究的目的:
- 评估TAK-994的疗效和安全性,TAK-994是一种口服素受体2-选择性激动剂,用于麻醉症1型患者.
- 评估TAK-994对睡眠延迟,白天嗜睡和触发症的影响.
主要方法:
- 一个2期,随机的,安慰剂对照试验进行了,其中73名患者被诊断患有1型麻醉症.
- 患者每天两次口服TAK-994 (30毫克,90毫克或180毫克) 或安慰剂,持续8周.
- 主要终点:在保持清醒测试 (MWT) 中平均睡眠延迟的变化. 二级终点:爱普沃思嗜睡量表 (ESS) 评分的变化和每周触角症的发生率.
主要成果:
- 与安慰剂相比,TAK-994在所有测试剂量中显著改善了MWT上的睡眠延迟 (P<0.001).
- 接受TAK-994治疗的患者在ESS得分上表现出显著的降低,这表明白天嗜睡程度下降.
- 与安慰剂相比,TAK-994组的每周触感率明显较低,具有显著的剂量依赖效应.
- 报告了肝脏不良事件,包括5名患者的临床重要肝酶升高和3名患者的药物诱导肝损伤.
结论:
- TAK-994在改善1型麻醉症的关键症状方面表现出显著的有效性,包括嗜睡和触发性.
- 该试验因在接受TAK-994.4治疗的患者中观察到的肝毒性相关的安全问题而提前终止.
- 需要对素受体激动剂的风险益处概况进行进一步的研究.
相关概念视频
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Narcolepsy
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
REM Sleep Behavior Disorder
RBD is significantly associated with...
Opioid Receptors: Overview

